Keros Therapeutics, Inc. (KROS) Operating income 2019–2025
Keros Therapeutics, Inc. (KROS) annual operating income history from SEC filings — each fiscal year as reported.
$67.6MFY2025 · since FY2019: -$10.6M → $67.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $67.6M | +132.0% |
| FY2024 | -$210.8M | -24.1% |
| FY2023 | -$169.9M | -48.0% |
| FY2022 | -$114.8M | -103.6% |
| FY2021 | -$56.4M | -20.8% |
| FY2020 | -$46.7M | -341.7% |
| FY2019 | -$10.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS RevenueKROS Net incomeKROS Net marginKROS Gross profitKROS Gross marginKROS Operating marginKROS Operating cash flowKROS Free cash flowKROS Capital expendituresKROS Return on equityKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →